valganciclovir and Anemia--Hemolytic--Autoimmune

valganciclovir has been researched along with Anemia--Hemolytic--Autoimmune* in 1 studies

Other Studies

1 other study(ies) available for valganciclovir and Anemia--Hemolytic--Autoimmune

Article	Year
Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica, 2006, Volume: 91, Issue:5 Suppl A 58-year-old man with warm-antibody-mediated autoimmune hemolytic anemia (AIHA) refractory to prednisolone, azathioprine, splenectomy, rituximab and combination chemotherapy, and with unacceptably high transfusion requirement, was treated with alemtuzumab. After a cumulative dose of 883 mg of alemtuzumab, the AIHA remitted completely, with normalization of hemoglobin and transfusion-independence. The major side effect was reactivation of cytomegalovirus, which was controlled with intravenous and oral ganciclovir. This case showed that alemtuzumab might be of use in therapy-refractory AIHA. Topics: Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antiviral Agents; Azathioprine; Blood Transfusion; CD52 Antigen; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance; Ganciclovir; Glycoproteins; Humans; Immunosuppressive Agents; Male; Middle Aged; Prednisolone; Remission Induction; Rituximab; Splenectomy; Valganciclovir; Viremia; Virus Activation	2006

Article

Year

Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.

Haematologica, 2006, Volume: 91, Issue:5 Suppl

A 58-year-old man with warm-antibody-mediated autoimmune hemolytic anemia (AIHA) refractory to prednisolone, azathioprine, splenectomy, rituximab and combination chemotherapy, and with unacceptably high transfusion requirement, was treated with alemtuzumab. After a cumulative dose of 883 mg of alemtuzumab, the AIHA remitted completely, with normalization of hemoglobin and transfusion-independence. The major side effect was reactivation of cytomegalovirus, which was controlled with intravenous and oral ganciclovir. This case showed that alemtuzumab might be of use in therapy-refractory AIHA.

Topics: Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antiviral Agents; Azathioprine; Blood Transfusion; CD52 Antigen; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance; Ganciclovir; Glycoproteins; Humans; Immunosuppressive Agents; Male; Middle Aged; Prednisolone; Remission Induction; Rituximab; Splenectomy; Valganciclovir; Viremia; Virus Activation

2006